Pharmaceutical formulations for the treatment of alzheimer's disease
View Patent ↗The present invention relate to pharmaceutical formulations that include a CPHPC component and a delivery agent compound.
1. A transdermal pharmaceutical composition comprising a delivery agent, CPHPC, and a solvent, wherein the delivery agent is selected from N-(8-[2-hydroxybenzoyl]amino)caprylic acid, pegylated-N-(8-[2-hydroxybenzoyl]amino)caprylic acid, and pharmaceutically acceptable salts thereof, the pharmaceutical composition is suitable for transdermal administration, and the pharmaceutical composition delivers a dose of CPHPC of between about 1 mcg/cm 2 /day and about 500 mcg/cm 2 /day.
2. The transdermal pharmaceutical composition of claim 1 , wherein the solvent is selected from ethanolamine, a pH 8.1 buffer, deionized water, an alcohol, a fatty acid/fatty acid ester blend, isopropyl palmitate, isopropyl mystristate, mineral oil, a silicone fluid, an organic amine, a plasticizer, and combinations thereof.
3. The transdermal pharmaceutical composition of claim 1 , wherein the delivery agent is N-(8-[2-hydroxybenzoyl]-amino) caprylic acid or a pharmaceutically acceptable salts thereof.
4. The transdermal pharmaceutical composition of claim 3 , wherein the delivery agent is a sodium salt of N-(8-[2-hydroxybenzoyl]amino)caprylic acid.
5. The transdermal pharmaceutical composition of claim 1 , wherein the pharmaceutical formulation provides sustained release of the CPHPC component.
6. A method of treating amyloid accumulation in a mammal in need thereof comprising transdermally administering to the mammal an effective amount of the pharmaceutical formulation of claim 1 .
7. The method of claim 6 , wherein the amyloid accumulation is due to Alzheimer's Disease.
8. A method of treating a disorder associated with excessive deposition of amyloid in a mammal comprising transdermally administering to the mammal an effective amount of the pharmaceutical formulation of claim 1 .
9. A method of inhibiting amyloid deposition in a mammal with Alzheimer's Disease or Amyloidosis comprising transdermally administering to the mammal an effective amount of the pharmaceutical formulation of claim 1 .
10. A method of treating amyloid deposition in a mammal with Alzheimer's Disease or Amyloidosis comprising transdermally administering to the mammal an effective amount of the pharmaceutical formulation of claim 1 .
11. A method of reducing amyloid deposition in a mammal with Alzheimer's Disease or Amyloidosis comprising transdermally administering to the mammal an effective amount of the pharmaceutical formulation of claim 1 .
12. A method for administering a CPHPC component to a mammal in need thereof comprising transdermally administering to the mammal the pharmaceutical formulation of claim 1 .
13. A method of treating amyloid deposition in a mammal with diabetes, dementia or medullary carcinoma of the thyroid comprising transdermally administering to the mammal an effective amount of the pharmaceutical formulation of claim 1 .
14. The transdermal pharmaceutical composition of claim 1 , wherein the pharmaceutical composition delivers a dose of CPHPC of between about 8 mcg/cm 2 /day and about 21 mcg/cm 2 /day.
15. The transdermal pharmaceutical composition of claim 1 , wherein the pharmaceutical composition delivers a dose of CPHPC of about 5.1 mcg/cm 2 /day, about 6.2 mcg/cm 2 /day, about 241 mcg/cm 2 /day, or about 420 mcg/cm 2 /day.